An Overview on a new generation LDL-C lowering drug: Inclisiran and its market forecast
Asiya Parveen, Mohammad Shahar Yar, Nadeem Siddiqui, Vivek Kumar, Najmussehar, Shazia Parveen · World Journal of Biology Pharmacy and Health Sciences · 2024
Inspite of the broadly available efficacious lipid-lowering drugs, atherosclerotic cardiovascular disease still remains a universal health issue. LDL-C represents an essential part in pathological process of atherosclerotic disease. High concentrations of plasma have been correlated with 50-70 % increase in progression of atherosclerotic plagues in patients with or without undistinguished cardiovascular risk. FDA has approved Novartis Leqvio (Inclisiran) first -in class siRNA to lower cholesterol and maintain it low with two doses a year. Inclisiran is a small interfering RNA (siRNA) molecule, targeting the hepatic production of PCSK9 results in lowering of LDL. The review displays the current scientific information referring to inclisiran as a new favourable weapon in the control of hypercholesterolemia and insights to its global market forecast.